In addition, a study presented recently at the American Association for Cancer Research, 101st Annual Meeting [44], revealed that, in patients with serous epithelial ovarian carcinoma, pretreatment tumor expression of various genes within the TNF-α and NF-κB signaling networks could be used to distinguish between responders and nonresponders to paclitaxel/carboplatin chemotherapy. This evidence concerns the gene NFKB1 and cancer.